Overview

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer
Phase:
PHASE1
Details
Lead Sponsor:
Qiu Guoqin
Treatments:
Carboplatin
Paclitaxel
Radiotherapy
tislelizumab